摘要
目的:探讨阿托伐他汀早期干预治疗对糖尿病合并急性冠脉综合征病人血清SCD40L水平的影响。方法:80例糖尿病合并急性冠脉综合征患者随机分为两组:A组为常规治疗组(40例),予以常规治疗但不用降脂药物;B组(40例)为40mg阿托伐他汀治疗组;20例稳定性心绞痛患者为对照组。80例糖尿病合并急性冠脉综合征在治疗2周前后分别测定血清sCD40L及血脂水平。结果:80例糖尿病合并急性冠脉综合征患者的血清sCD40L水平明显高于稳定性冠心病患者(P<0.05),B组治疗2周后血清sCD40L显著下降(P<0.05)。结论:糖尿病合并急性冠脉综合征患者血清sCD40L水平增高,早期阿托伐他汀治疗能明显降低糖尿病合并急性冠脉综合征患者的血清sCD40L水平,对减轻炎症反应、稳定斑块有一定作用。
Objective：To investigate the effect of atorvastatin on the serum level of sCD40 ligand in diabetic patients with acute coronary syndrome.Methods：80 diabetic patients swith acute coronary syndrome were randomly separated into two groups.40 patients in group A were given routine therapy;40 patients in group B were given routine therapy and 40mg atorvastatin once daily for 2 weeks,Twenty patients with stable angi-Na served controls.The seruml evels of sCD40L before and after therapy were measure dwith ELISA method.Results：The serum levels of sCD40L in the diabetic patients with acute coronary syndrome were significantly higher than those in control group（P〈005）.The serum levels of sCD40L were significantly lowered after two weeks of therapy ingroup B （P〈005）.While no significant difference was observed before and after treatment in group A.Conclusion：The serum levels of sCD40Lis increased in the diabetic patients with acute coronary syndrome and earlys imvastatin intervention may significantly decrease the serum levels of sCD40L.Early intensive atorvastatin which may benefit to the stabilization of atherosclerotic plaquel.
